The present disclosure relates to a bio-material composition comprising a dry potassium phosphate based mixture omprising: MgO, monobasic potassium phosphate, monobasic sodium phosphate, proteoglycans, calcium sodium phosphosilicate, and an antibiotic, wherein a weight percent ratio of monobasic potassium phosphate to MgO is between about 3:1 and 1:1, wherein the dry otassium phosphate based mixture is configured to be mixed with the aqueous solution to thereby form a reabsorbable bio-material slurry, wherein the proteoglycans are between about 1-10 weight percent of the dry composition, and wherein the proteoglycans act as active regulators of collagen fibrillogenesis to thereby structure tissue of a patient by organizing a bone extracellular matrix.

Artificial meniscal scaffolds characterized by a composite of circumferential polymer fiber network and orthogonal polymer fiber network embedded in an arcuate bioresorbable matrix comprised of collagen and hyaluronic acid. The orthogonal polymer fiber network prevents separation of the circumferential polymer fiber networks. The polymer fiber networks convert axial compressive forces on the scaffolds to tensile loads on the circumferential polymer fibers. The composite scaffold can be anchored to bone by novel anchoring components that protect the polymer fibers and ensure immediate securement of the artificial meniscal scaffold to bone.

Artificial meniscal scaffolds characterized by a composite of circumferential polymer fiber network and orthogonal polymer fiber network embedded in an arcuate bioresorbable matrix comprised of collagen and hyaluronic acid. The orthogonal polymer fiber network prevents separation of the circumferential polymer fiber networks. The polymer fiber networks convert axial compressive forces on the scaffolds to tensile loads on the circumferential polymer fibers. The composite scaffold can be anchored to bone by novel anchoring components that protect the polymer fibers and ensure immediate securement of the artificial meniscal scaffold to bone.

Medical devices, substrates and biologic therapies for bone repair and guided tissue regeneration are disclosed. More particularly, bone graft substitutes and bone void fillers which comprise a porous collagen matrix and calcium deficient hydroxyapatite ceramic granules for delivery of osteoinductive or other therapeutic agents are disclosed.

A method for controlling generation of biologically desirable voids in a composition placed in proximity to bone or other tissue in a patient by selecting at least one water-soluble inorganic material having a desired particle size and solubility, and mixing the water-soluble inorganic material with at least one poorly-water-soluble or biodegradable matrix material. The matrix material, after it is mixed with the water-soluble inorganic material, is placed into the patient in proximity to tissue so that the water-soluble inorganic material dissolves at a predetermined rate to generate biologically desirable voids in the matrix material into which bone or other tissue can then grow.

A method for promoting growth of bone, periodontium, ligament, or cartilage in a mammal by applying to the bone, periodontium, ligament, or cartilage a composition comprising platelet-derived growth factor at a concentration in the range of about 0.1 mg/mL to about 1.0 mg/mL in a pharmaceutically acceptable liquid carrier and a pharmaceutically-acceptable solid carrier.

The present invention pertains to novel bone graft substitute materials. These materials are porous, homogenously dispersed solid mixtures of calcium phosphate and pro-regenerative extracellular matrix (ECM)—and potentially any pharmaceutical agent and/or mineral—that have been infused with polydopamine. In some embodiments the bone graft materials have osteoinductive factors incorporated within them.

The present invention relates to a method for producing hydroxyapatite-bioglass macroporous material, to said materials, and to medical devices thereof.

The method comprises a step of preparation of an aqueous suspension of hydroxyapatite and bioglass with a porogenic agent, and subsequent sintering to achieve a macroporous biomaterial.

The macroporous structure of these materials enhances blood vessels and bone cells migration, allowing bone growth through the interior of the bone substitute, thereby increasing the rate of formation of new bone at the site of implantation. Therefore, these materials are advantageously used to produce medical devices, such as bone grafts that resemble the mineral phase of natural bone showing improved mechanical strength and osteoconductivity.

The biomaterials of the present invention are applicable in the medical area, in particular in bone regeneration and reparation techniques as bone grafts.

Compositions of small molecules, matrices, and isolated cells including methods of preparation, and methods for differentiation, trans-differentiation, and proliferation of animal cells into the osteoblast cell lineage were described. Examples of osteogenic materials that were administered to cells or co-cultured with cells are represented by compounds of Formula II, IV, and VI independently or preferably in combination with a matrix to afford bone cells. Small molecule-stimulated cells were also combined with a matrix, placed with a cellular adhesive or material carrier and implanted to a site in an animal for bone repair. Matrix pretreated with compounds of Formula II, IV, and VI were also used to cause cells to migrate to the matrix that is of use for therapeutic purposes.

The present disclosure provides devices comprising a therapeutic agent bound to a printed three-dimensional structure. The printed three-dimensional structure comprises about 50% to about 100% by weight ceramic and about 0% to about 50% by weight N polymer. Ink formulations for three-dimensional printing are also disclosed. Additionally, provided herein are methods for manufacturing devices and uses thereof, e.g., in treating a condition in a subject in need thereof.